Manuscripts and Publications

Filters: Author is Ortega, Victor E  [Clear All Filters]
2022
W LeMaster B, P Quibrera M, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG et al..  2022.  Clinical implications of low absolute blood eosinophil count in the SPIROMICS COPD cohort. Chest.
Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG et al..  2022.  Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. Chronic Obstr Pulm Dis. 9(2):111-121.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Godbole S, Labaki WW, Pratte KA, Hill A, Moll M, Hastie AT, Peters SP, Gregory A, Ortega VE, Demeo D et al..  2022.  A Metabolomic Severity Score for Airflow Obstruction and Emphysema.. Metabolites. 12(5)
Esther CR, O'Neal WK, Alexis NE, Koch AL, Cooper CB, Barjaktarevic I, Raffield LM, Bowler RP, Comellas AP, Peters SP et al..  2022.  Prolonged, Physiologically Relevant Nicotine Concentrations in the Airways of Smokers. Am J Physiol Lung Cell Mol Physiol.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
2021
Ejike CO, Woo H, Galiatsatos P, Paulin LM, Krishnan JA, Cooper CB, Couper DJ, Kanner RE, Bowler RP, Hoffman EA et al..  2021.  Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes.. Am J Respir Crit Care Med. 203(8):987-997.
Moughames E, Woo H, Galiatsatos P, Romero-Rivero K, Raju S, Tejwani V, Hoffman EA, Comellas AP, Ortega VE, Parekh T et al..  2021.  Disparities in access to food and chronic obstructive pulmonary disease (COPD)-related outcomes: a cross-sectional analysis.. BMC Pulm Med. 21(1):139.
Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ et al..  2021.  Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.. Genome Med. 13(1):66.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Gillenwater LA, Kechris KJ, Pratte KA, Reisdorph N, Petrache I, Labaki WW, O'Neal W, Krishnan JA, Ortega VE, DeMeo DL et al..  2021.  Metabolomic Profiling Reveals Sex Specific Associations with Chronic Obstructive Pulmonary Disease and Emphysema.. Metabolites. 11(3)
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.
Woo H, Brigham EP, Allbright K, Ejike C, Galiatsatos P, Jones MR, Oates GR, Krishnan JA, Cooper CB, Kanner RE et al..  2021.  Racial Segregation and Respiratory Outcomes among Urban Black Residents with and at Risk of Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 204(5):536-545.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
2020
Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, R Barr G, Krishnan JA, Cooper C, Labaki WW et al..  2020.  Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.. Chest. 157(4):856-865.
Putcha N, Fawzy A, Matsui EC, Liu MC, Bowler RP, Woodruff PG, O'Neal WK, Comellas AP, Han MK, Dransfield MT et al..  2020.  Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene.. Chest. 158(6):2333-2345.
Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, Barjaktarevic I, Basta P, Clish CB, Comellas AP et al..  2020.  Comparison of Proteomic Assessment Methods in Multiple Cohort Studies.. Proteomics. 20(12):e1900278.
Stott-Miller M, Müllerová H, Miller B, Tabberer M, Baou CEl, Keeley T, Martinez FJ, Han ML, Dransfield M, Hansel NN et al..  2020.  Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:2467-2476.
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
Gillenwater LA, Pratte KA, Hobbs BD, Cho MH, Zhuang Y, Halper-Stromberg E, Cruickshank-Quinn C, Reisdorph N, Petrache I, Labaki WW et al..  2020.  Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules.. Netw Syst Med. 3(1):159-181.
Strand M, Austin E, Moll M, Pratte KA, Regan EA, Hayden LP, Bhatt SP, Boriek AM, Casaburi R, Silverman EK et al..  2020.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.. Chronic Obstr Pulm Dis. 7(4):346-361.

Pages